key: cord-0714747-iuvm3fix authors: Rutkowski, Krzysztof; Mirakian, Rita; Till, Stephen; Rutkowski, Ryszard; Wagner, Annette title: Adverse reactions to COVID‐19 vaccines: A practical approach date: 2021-04-14 journal: Clin Exp Allergy DOI: 10.1111/cea.13880 sha: 46b6942714fcc71986f17eabe0da1173d981bdf7 doc_id: 714747 cord_uid: iuvm3fix COVID‐19‐related mortality in high‐risk individuals is substantial and current treatment options are limited. There is convincing evidence that the COVID‐19 vaccines reduce the severity of infection and prevent deaths. Three COVID‐19 vaccines are approved in the United Kingdom with many more in development. There are limited data on the triggers and mechanisms of anaphylaxis to these vaccines. We review the potential allergenic compounds in the COVID‐19 vaccines and describe an innovative allergy support model for the vaccination hubs that allows most patients with severe allergy be immunized. Finally, we propose a practical algorithm for the investigations of anaphylaxis to these vaccines. imperative is to vaccinate as many people as possible. Not unexpectedly, adverse reactions, including anaphylaxis have been reported within 24 hours of the start of the rollout of vaccination, causing major concerns. We describe an innovative allergy support model for the COVID vaccination hubs (Figure 1 ). Immediate remote access to an allergist helps non-allergists running the hubs manage (vaccine) allergy concerns, minimizes the risk of patients unnecessarily being denied vaccination and protects those patients at high risk of an allergic reaction, particularly to the excipients in the vaccines, from inadvertent exposure. We propose a practical algorithm for the investigations of patients with a history of allergy to an excipient in the currently approved COVID vaccines as well patients who experienced hypersensitivity reaction to the first dose of the vaccine ( Figure 2 ). As detailed allergy workup data emerges, these algorithms are likely to be simplified. This will aid the medical community reach the ultimate goal of vaccinating the entire population in a safe and time and cost-efficient manner. nanoparticles. 4, 5 The clinical trials with both vaccines have shown their safety and efficacy with a low incidence of adverse events. It is important to note that Pfizer and Moderna excluded individuals with a history of allergic reaction to vaccines or components of their vaccines from the phase 3 trials. Individuals with previous allergic reactions to food or medications were not excluded. 4, 5 The ChAdOx1 vaccine uses a more conventional, chimpanzee modified Adenovirus vector which also contains the genetic sequence of the surface spike protein. The trial exclusion criteria included history of allergic disease or reactions likely to be exacerbated by any component of ChAdOx1 or MenACWY (Meningococcal group A, C, W-135 and Y conjugate vaccine) and any history of angioedema and/or of anaphylaxis. 6 ing anaphylaxis has been a cause for concern. 11 5 | PEG ALLERGY The molecular weight of PEGs varies from a few hundreds to more than 30 000 g/mol and beyond. Allergenicity correlates with an in- EMA and FDA also agree that only patients with previously documented hypersensitivity reactions to the COVID vaccine or any of its ingredients/excipients should not be vaccinated. All tests should be performed by an allergist/immunologist experienced in the diagnosis of PEG allergy. Standardized ST protocols and in vitro tests are a work in progress and individual patients may need tailored testing regimes, 9, 10 • Skin testing should be tailored to the suspected mechanism of the reaction, for example SPT and IDT with immediate reading for immediate reactions and IDT with late reading and patch test for The Moderna vaccine, in addition to PEG, contains trometamol (tromethamine) known to cause not only contact dermatitis but also immediate hypersensitivity reactions. It is present in enteral and parenteral drugs: cotrimoxazole iv, Humalog insulin, Menitorix (Haemophilus type b and meningococcal group C conjugate) vaccine, midazolam, oxaliplatin as well as MRI and CT radiocontrast media. 30 The allergenic potential of other excipients: 1,2-distearoyl-sn-glyce ro-3-phosphocholine (DSPC) and EDTA needs to be considered. 31 However, testing faces the same challenges as for PEG, due to the lack of standardized, commercially available test solutions. Hypersensitivity reactions should be managed depending on their severity and according to the relevant guidelines. 32 Adverse reactions will definitely continue to emerge. Systematic monitoring, detailed documentation and characterization of all potential anaphylactic events (immunological and nonimmunological) will be critical in delineating underlying mechanisms and informing future recommendations for safe vaccine administration. All authors declare no relevant conflicts of interest. All authors contributed equally to this work. Krzysztof Rutkowski https://orcid.org/0000-0002-2350-8697 The Inclusive Review on SARS-CoV-2 Biology, Epidemiology, Diagnosis, and Potential Management Options Immunisation against infectious disease. COVID-19 Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Online ahead of print Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine Immediate type hypersensitivity to polyethylene glycols: a review Polyethylene glycol may be the major allergen in depot medroxyprogesterone acetate Polyethylene glycol: not just a harmless excipient Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized Steroid allergy: clinical features and the importance of excipient testing in a diagnostic algorithm Immediate hypersensitivity reactions to steroids and steroid containing medications COVID-19 vaccine anaphylaxis: PEG or not? COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to MMWR 1 Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine -United States Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine MMWR2 allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 Vaccine -United States Risk of anaphylaxis after vaccination in children and adults Anaphylaxis after vaccination reported to the VAERS 1990-2016 Vaccine allergy: a decade of experience from 2 large UK allergy centers Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines Who is really at risk for anaphylaxis due to COVID-19 vaccine? Vaccines Immediate hypersensitivity to polyethylene glycols in unrelated products: when standardization in the nomenclature of the components of drugs, cosmetics, and food becomes necessary Anti-PEG IgE in anaphylaxis associated with polyethylene glycol Polyethylene glycol and polysorbate skin testing in the evaluation of COVID-19 vaccine reactions: early report Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation PEGylated liposomes: immunological responses Immunological and toxicological considerations for the design of liposomes Anaphylaxis to trometamol excipient in gadolinium-based contrast agents for clinical imaging Systemic allergy to EDTA in local anesthetic and radiocontrast media Resuscitation Council UK. Anaphylaxis guidance for vaccination settings 2021 Non-irritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines Adverse reactions to COVID-19 vaccines: A practical approach